Generation of human anti-MUC3 IgG antibodies after in vitro immunization of naive peripheral blood B-lymphocytes

被引:4
作者
Baritaki, S
Zafiropoulos, A
Georgopoulou, E
Souris, S
Krambovitis, E
机构
[1] FORTH, Dept Appl Biochem & Immunol, IMBB, Heraklion 71110, Crete, Greece
[2] DAU Penlelis Hosp, Dept Haematol & Histol, Athens, Greece
[3] Apollonion Gen Hosp, Dept Pathol, Heraklion, Greece
关键词
MUC3; human antibody; in vitro immunization; fluorometry; immunohistology;
D O I
10.1007/PL00006681
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
It has been demonstrated that IgG antibodies can be generated to self-antigen peptides as well as against viral antigens by an antigen-specific in vitro immunization system of resting human peripheral B-lymphocytes. Using a synthetic peptide from the consensus variable tandem-repeat region of the MUC3 mucin (TSSITTTGTTSHSTPSP) as the B cell epitope, we immunized blood donor B-lymphocytes in vitro and tested for MUC3-specific antibodies by ELISA. After the primary activation step all antibodies were IgM. At the end of the secondary immunization step we obtained 1.8% (21/1138) of the cultures with IgG-switched antibodies. In a competitive inhibition ELISA using the MUC1, MUC2, MUC3, MUC4 and PIP2 peptides, only one culture (F8.1) gave satisfactory specific inhibition. Using this antibody in fluorometric studies, it stained cells from two colon carcinoma cell lines predominantly in the cytoplasm. whereas those from a breast cancer cell line stained predominantly the cell surface. In a preliminary immunohistological evaluation with formalin-fixed sections, the antibody appeared to moderately stain colon sections, but not breast sections or lymph node. This method of in vitro immunization may be a useful tool in generating IBG antibodies specific to self-antigens and could find applications in tumour targeting and immunotherapy.
引用
收藏
页码:109 / 114
页数:6
相关论文
共 19 条
[1]   A tandem repeat of MUC1 core protein induces a weak in vitro immune response in human B cells [J].
Andersson, E ;
Henderikx, P ;
Krambovitis, E ;
Hoogenboom, HR ;
Borrebaeck, CAK .
CANCER IMMUNOLOGY IMMUNOTHERAPY, 1999, 47 (05) :249-256
[2]   Breast cancer immunotherapy: Current status and future prospects [J].
Apostolopoulos, V ;
McKenzie, IFC ;
Pietersz, GA .
IMMUNOLOGY AND CELL BIOLOGY, 1996, 74 (05) :457-464
[3]   PRODUCTION OF ANTI-BREAST CANCER MONOCLONAL-ANTIBODIES USING A GLUTATHIONE-S-TRANSFERASE-MUC1 BACTERIAL FUSION PROTEIN [J].
APOSTOLOPOULOS, V ;
XING, PX ;
TRAPANI, JA ;
MCKENZIE, IFC .
BRITISH JOURNAL OF CANCER, 1993, 67 (04) :713-720
[4]  
AUGERON C, 1984, CANCER RES, V44, P3961
[5]   MUCINS - STRUCTURE, FUNCTION, AND ASSOCIATIONS WITH MALIGNANCY [J].
DEVINE, PL ;
MCKENZIE, IFC .
BIOESSAYS, 1992, 14 (09) :619-625
[6]   MOLECULAR-CLONING OF CDNAS DERIVED FROM A NOVEL HUMAN INTESTINAL MUCIN GENE [J].
GUM, JR ;
HICKS, JW ;
SWALLOW, DM ;
LAGACE, RL ;
BYRD, JC ;
LAMPORT, DTA ;
SIDDIKI, B ;
KIM, YS .
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1990, 171 (01) :407-415
[7]   Antibody and T cell responses of patients with adenocarcinoma immunized with mannan-MUC1 fusion protein [J].
Karanikas, V ;
Hwang, LA ;
Pearson, J ;
Ong, CS ;
Apostolopoulos, V ;
Vaughan, H ;
Xing, PX ;
Jamieson, G ;
Pietersz, G ;
Tait, B ;
Broadbent, R ;
Thynne, G ;
McKenzie, IFC .
JOURNAL OF CLINICAL INVESTIGATION, 1997, 100 (11) :2783-2792
[8]   Preparation of MUC-1 oligomers using an improved convergent solid-phase peptide synthesis [J].
Krambovitis, E ;
Hatzidakis, G ;
Barlos, K .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1998, 273 (18) :10874-10879
[9]   Immunocytochemical and flow cytofluorimetric detection of intracellular IL-4, IL-5 and IFN-gamma: Applications using blood- and airway-derived cells [J].
Krouwels, FH ;
Nocker, RET ;
Snoek, M ;
Lutter, R ;
vanderZee, JS ;
Weller, FR ;
Jansen, HM ;
Out, TA .
JOURNAL OF IMMUNOLOGICAL METHODS, 1997, 203 (01) :89-101
[10]  
OHLIN M, 1989, IMMUNOLOGY, V66, P485